A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis
Terminated
- Conditions
- Amyotrophic Lateral Sclerosis
- Registration Number
- NCT00213824
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
This is a study of the expression of nogo and reticulon genes in the skeletal muscle of patients with amyotrophic lateral sclerosis (ALS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 79
Inclusion Criteria
- Patients with definite ALS
- Males or females
- Age > 18
Exclusion Criteria
- Patients with other neuromuscular affections
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link Nogo and Reticulon gene expression to ALS progression in skeletal muscle?
Are Nogo and Reticulon proteins potential therapeutic targets for ALS treatment development?
How do Nogo and Reticulon gene expression levels compare to other biomarkers in ALS patient stratification?
What adverse events are associated with Nogo/Reticulon pathway modulation in neuromuscular diseases?
What combination therapies with Nogo/Reticulon inhibitors show promise in preclinical ALS models?
Trial Locations
- Locations (1)
Clinique Neurologique, Service des Maladies du Système Nerveux et du Muscle, Hôpital Civil, Hôpitaux Universitaires
🇫🇷Strasbourg, France
Clinique Neurologique, Service des Maladies du Système Nerveux et du Muscle, Hôpital Civil, Hôpitaux Universitaires🇫🇷Strasbourg, France